DUBLIN--(BUSINESS WIRE)--The "Clinical Trials Market Forecast Report by Phase, Indication, Study Material, Country and Company 2025-2033" report has been added to ResearchAndMarkets.com's offering.
In reinstating human ADME to its portfolio, SGS strengths its ability to support drug development programmes with critical early clinical data. FANC approval enables SGS to reintroduce ¹⁴C human ADME ...
ANTWERP, BELGIUM, February 16, 2026 /EINPresswire.com/ — SGS today announced it has received formal approval from the Belgian Federal Agency for Nuclear Control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results